The proposed bill enacts R.S. 22:1076.1, establishing an advisory board within the Louisiana Department of Insurance dedicated to reviewing and providing medical recommendations for new treatments for rare cancers. The board will consist of various members, including representatives from the Louisiana Department of Health, the Louisiana Association of Health Plans, and several medical institutions specializing in oncology. Additionally, the board will include two oncologists who focus on rare cancer treatments.

The advisory board is mandated to hold quarterly public meetings and must compile and submit a formal report of its findings to the legislature within thirty days of each meeting. The chairperson of the board will be the executive director of the Louisiana Cancer Research Center, and the commissioner is authorized to adopt necessary administrative rules to implement the provisions of this section. This initiative aims to enhance the approval process for rare cancer treatments and ensure that medical recommendations are based on expert input from a diverse group of stakeholders.